Helius Medical Technologies, Inc. (NASDAQ:HSDT) is reporting second quarter financial results on Wednesday 12th August 2020, after market close.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 2.00 million ~ $ 2.00 million
Click Here For More Historical Outlooks Of Helius Medical Technologies, Inc.
Previous Quarter Performance
Helius Medical Technologies, Inc. unfold loss for the first quarter of $ 0.15 per share, from the revenue of $ 0.21 million. The quarterly earnings down 22.38 percent while revenues compared with the same quarter last year.
Wall street analysts are predicting revenue of The bottom line results street analysts by $ 0.02 or , at the same time, top line results analysts by $ 9.40 million or .
Historical Earnings Performance
wpDataChart with provided ID not found! wpDataTable with provided ID not found!Click Here For More Historical Earnings Of Helius Medical Technologies, Inc.
Stock Performance
According to the previous trading day, closing price of HSDT was $ 0.53, representing a 112.00 % increase from the 52 week low of $ 0.25 and a 75.69 % decrease over the 52 week high of $ 2.18.
The company has a market capital of $ 19.89 million and is part of the Healthcare sector and Medical Devices industry.
[stock_market_widget type=”chart” template=”basic” color=”orange” assets=”HSDT” range=”1y” interval=”1mo” axes=”true” cursor=”true” api=”yf” style=”height: 400px;”]
Conference Call
Helius Medical Technologies, Inc. will be hosting a conference call at 5:00 PM eastern time on 12th August 2020, to discuss its 2Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website heliusmedical.com
Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, or acquiring noninvasive technologies for the treatment of symptoms caused by neurological disease or trauma. The companys product is Portable Neuromodulation Stimulator, a medical device in Canada for the treatment of chronic balance deficit associated with a mild to moderate traumatic brain injury. Its PoNS device treats neurostimulation of cranial nerves via the tongue to restore lost function.
